| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 09/30/2004 | WO2004082631A2 METHODS FOR PREPARATION AND USE OF 1α,24(S)-DIHYDROXYVITAMIN D2 |
| 09/30/2004 | WO2004082595A2 Therapeutic use of tumor necrosis factor-alpha mutein |
| 09/30/2004 | WO2004082588A2 Dispersible formulation of an anti-inflammatory agent |
| 09/30/2004 | WO2004082586A2 Phamaceutical compositions comprising inhibitors of fab i and further antibiotics |
| 09/30/2004 | WO2004082579A2 Nemorubicin as radiosensitizer in combination with radiation therapy against tumors |
| 09/30/2004 | WO2004064820A3 Use of sphingolipids for reducing plasma cholesterol and triacylglycerol levels |
| 09/30/2004 | WO2004064815A8 Oral dosage formulation |
| 09/30/2004 | WO2004064785A9 Cancer therapy sensitizer |
| 09/30/2004 | WO2004062659A8 Methods and compositions for preventing/reducing the severity of side effects of chemotherapy and/or radiotherapy |
| 09/30/2004 | WO2004052308A3 Topical anti-infective formulations |
| 09/30/2004 | WO2004045523A3 Combination administration of an indolinone with a chemotherapeutic agent for cell proliferation disorders |
| 09/30/2004 | WO2004032849A3 Methods of administering fgf18 |
| 09/30/2004 | WO2003097806A3 Substituted 4-aryl-4h-pyrrolo[2,3-h]chromenes and analogs as activators of caspases and inducers of apoptosis and the use thereof |
| 09/30/2004 | WO2003088903A3 Compounds, compositions, and methods |
| 09/30/2004 | WO2003087333A8 Modulation of stem and progenitor cell differentiation, assays, and uses thereof |
| 09/30/2004 | WO2003072740A3 Novel type-1 cytokine receptor glm-r |
| 09/30/2004 | WO2003068197A8 Method for systemic drug delivery through the nail |
| 09/30/2004 | US20040192961 such as 2-nitrophenol by reacting 3-hydroxy-4-methoxybenzophenone with alkyl nitrate in presence of regioselective acid catalyst (sulfuric acid) |
| 09/30/2004 | US20040192926 Substituted indolyl quinolinone compounds; angiogenesis inhibitors; antitumor agents; atherosclerosis; vision defects; antidiabetic agents; antiinflammatory agents |
| 09/30/2004 | US20040192900 Calicheamicin derivative-carrier conjugates |
| 09/30/2004 | US20040192784 Synergistic mixture; containing hydroxy-3-methylglutaryl/3-/ coenzyme a inhibitor |
| 09/30/2004 | US20040192783 Use of B-2 bronchodilator drugs |
| 09/30/2004 | US20040192776 Cationic lipid compositions targeting angiogenic endothelial cells |
| 09/30/2004 | US20040192774 Method for improving the well-being of poultry by in-ovo injection of carnitine |
| 09/30/2004 | US20040192772 Agent for treating the symptoms of dementia disorders and/or depression |
| 09/30/2004 | US20040192763 Central nervous system disorders; antidepressants; neurodegenative diseases; restless leg syndrome; antiepileptic agents; headaches; hearing disorders |
| 09/30/2004 | US20040192754 Administering serotonin inhibitors; such as ketanserin, ritanserin, mainserin, cyproheptadine, fluoxetine, olanzapine, ziprasidone |
| 09/30/2004 | US20040192746 Anticancer agents; central nervous system disorders; sexual disorders; antidiabetic agents; obesity; muscular disorders; alopecia; sepsis; autoimmune disease |
| 09/30/2004 | US20040192745 Method of treating amytrophic lateral sclerosis using melatonin |
| 09/30/2004 | US20040192726 Farnesyl protein transferase inhibitors for treating breast cancer |
| 09/30/2004 | US20040192722 Selective iGluR5 receptor antagonists |
| 09/30/2004 | US20040192711 Kinase inhibitor; therapy for leukemia, lymphoma; skin cancer; autoimmune diseases; antiinflammatory agents; sunscreen agents |
| 09/30/2004 | US20040192694 Use of COX-2 inhibitors as gastroprokinetics |
| 09/30/2004 | US20040192693 Antidiabetic agents; arteriosclerosis; cardiovascular disorders; anticholesterol agents; antidepressants; schizophrenia; antilipemic agents |
| 09/30/2004 | US20040192683 Active ingredient combination for treating a dependence on addictive substances or narcotics using medicaments |
| 09/30/2004 | US20040192675 Pharmaceutical compositions containing tiotropium salts and antihistamines and their use |
| 09/30/2004 | US20040192670 For inhibiting bone resorption, treating/preventing osteoporosis, and inhibiting vascular restenosis, diabetic retinopathy, macular degeneration, aniogenesis, atherosclerosis, arthritis, tumor growth and metastasis |
| 09/30/2004 | US20040192662 Topically administering tazarotene gel and corticoid cream |
| 09/30/2004 | US20040192660 Protocol for improving vision |
| 09/30/2004 | US20040192659 Sodium channel blocker binds SS1 or SS2 site of extracellular region; cyclooxygenase inhibitor; side effect reduction; tetrodotoxin or derivative |
| 09/30/2004 | US20040192654 use of nucleoside analogues as an effective treatment for acute or chronic myelogenous leukemia; (-)- beta -L-Dioxolane-Cytidine ( beta -L-oddC); (-)- beta -Dioxolane-5-fluoro-Cytidine (5-FddC) |
| 09/30/2004 | US20040192652 Pharmaceutical combinations and methods for the treatment of leukemia |
| 09/30/2004 | US20040192637 HPMPC [(S)-1-[3-hydroxy-2-(phosphonomethoxy)propyl]cytosine]; kits; cytotoxicity; inhibition against viral and/or cellular polymerases; treatment of non virus-associated cancers |
| 09/30/2004 | US20040192635 administration of acyl derivatives of 2'-deoxyadenosine, 2'-deoxyguanosine, 2'-deoxycytidine, and 2'-deoxythymidine; prevent or treat radiation, sunlight and mutagen-induced cellular damage, improve the healing of wounds, repair damaged tissues, physiological and and pathological tissues conditions |
| 09/30/2004 | US20040192621 Anti-tumor agent |
| 09/30/2004 | US20040192620 suppressing follicle maturation and ovulation and replacing the endogenous ovarian secretion of 17 beta-estradiol; 1,3,5 (10)-estratrien-3, 15 alpha ,16 alpha ,17 beta -tetrol for example; does not employ co-administration of a luteinizing hormone releasing hormone; less side effects |
| 09/30/2004 | US20040192607 Transcriptional regulation of the human beta3-adrenergic receptor gene |
| 09/30/2004 | US20040192600 Use of a specific COX-2 inhibitor, and/or a pharmaceutically acceptable salt and lung surfactant (SP-B and SP-C) for the production of medicaments for the treatment and/or prophylaxis of infant respiratory distress syndrome and adult respiratory distress syndrome |
| 09/30/2004 | US20040192584 Combination of an aldosterone receptor antagonist and a neutral endopeptidase inhibitor |
| 09/30/2004 | US20040192581 Applying a topical formulations prepared from lysostaphin and lantibiotics such as nisin that are effective in treating dermatological and wound infections without disrupting the balance of non-pathogenic and pathogenic populations of skin flora |
| 09/30/2004 | US20040191898 Trangenic diploid cell comprising mutation in kinase allele for use in screening modulator for treatment of anxiety, addiction, withdrawal syndrome, skeletal muscle spasms, convulsive seizures and epilepsy |
| 09/30/2004 | US20040191893 Implantable drug delivery system comprised of sealed thermoplastic polymer in association with permeable membrane; gene therapy; toxicity testing |
| 09/30/2004 | US20040191829 Comprises peptide associated with sugar transport protein for identifying modulators for treatment and prevention of cell proliferative disorder |
| 09/30/2004 | US20040191791 Comprises nucleotide sequences coding sodium voltage gated channels for identifying modulators for treatment of epilepsy; diagnosis of seizure disorders |
| 09/30/2004 | US20040191345 New formulations and use thereof |
| 09/30/2004 | US20040191342 Such as beta-caryophyllene extracted from plant oil |
| 09/30/2004 | US20040191338 Administration of capsaicinoids |
| 09/30/2004 | US20040191330 Daily skin care regimen |
| 09/30/2004 | US20040191328 Combination of gallium compounds with nonchemotherapeutic anticancer agents in the treatment of neoplasia |
| 09/30/2004 | US20040191320 Pulmonary formulation |
| 09/30/2004 | US20040191303 Inhibiting adhesion of cells to activated vascular endothelium from bloodstream; proteins and glycoproteins isolated from human or animal amniotic fluid, serum or urine |
| 09/30/2004 | US20040191274 Topical composition |
| 09/30/2004 | US20040191272 Methods and reagents for vaccination which generate a CD8 T cell immune response |
| 09/30/2004 | US20040191254 Administering compound to decrease epidermal growth factor activity; anticarcinogenic agents for thyroid cancer mediated by mutations in RET gene |
| 09/30/2004 | US20040191247 Use of il-18 inhibitors for treating or preventing cns injuries |
| 09/30/2004 | US20040191239 Treatment and prevention of reactive oxygen metabolite-mediated cellular damage |
| 09/30/2004 | US20040191238 Administering to patient an agent which triggers anion efflux in respiratory tissues via activation of a secretin receptor |
| 09/30/2004 | US20040191236 Administering antigen associated with disease, a dendritic cell binding agent specific for the antigen, and an autologous dendritic cell; immunotherapy |
| 09/30/2004 | US20040191234 Administering prebiotic such as fructo-oligosaccharide; measles prevention; vaccines; nutrients |
| 09/30/2004 | US20040191230 Pharmaceutical composition for the diagnosis, prevention or treatment of a tumoral pathology comprising an agent modulating the polymerization state of actin |
| 09/30/2004 | US20040191228 Methods of kidney transplantation utilizing developing nephric tissue |
| 09/30/2004 | US20040191225 Injecting isolated cell through needle into organ, tissue, or tumor; drug delivery; carrier aids in retention of cells at injection site, or a tissue sealant or film to seal; tissue engineering; gene therapy |
| 09/30/2004 | US20040191224 Storage in container; applying to a surface to be sanitized with a dispersing mechanism; poultry processing, medical equipment, aircraft |
| 09/30/2004 | US20040191223 Combinatorial methods for inducing cancer cell death |
| 09/30/2004 | US20040191218 Pharmaceutical compositions and methods for treating cancer |
| 09/30/2004 | US20040191212 Phosphate-binding polymers for oral administration |
| 09/30/2004 | US20040191211 Tissue-specific transporter inhibitor |
| 09/30/2004 | US20040191206 Methods for reduction of inflammation and erythema |
| 09/30/2004 | US20040191203 Cosmetic or dermatological composition comprising n-acylaminoamide derivatives |
| 09/30/2004 | US20040191185 Ephedrine or fenfluramine; aluminum foil coated with a thin layer of drug is heated to form vapor; which condenses to form aerosol; rapid peak plasma concentration |
| 09/30/2004 | US20040191184 Delivery of muscle relaxants through an inhalation route |
| 09/30/2004 | US20040191183 Delivery of antiemetics through an inhalation route |
| 09/30/2004 | US20040191182 Delivery of analgesics through an inhalation route |
| 09/30/2004 | US20040191181 Vaporization of diphenhydramine from solid for breathing administerig |
| 09/30/2004 | US20040191180 Breathing analgesics after vaporization for administering pain killer for headaches |
| 09/30/2004 | US20040191179 Breathing antidepressants from aerosols for administering bupropion by heating on a solid support |
| 09/30/2004 | US20040191176 Bronchodilator, vasoconstrictor, corticosteroid and optional carrier and drug delivery device for lungs |
| 09/30/2004 | DE10312061A1 Kombination von Phenylcarbonsäureamiden mit Blockern des IK-Kanals und deren Verwendung zur Behandlung von Vorhofarrhythmien Combination of phenylcarboxamides with the IK channel blockers and their use for the treatment of atrial arrhythmias |
| 09/30/2004 | CA2519589A1 Dispersible pharmaceutical composition for treatment of mastitis and otic disorders |
| 09/30/2004 | CA2519439A1 Compositions and methods for treating colic |
| 09/30/2004 | CA2519429A1 Pharmaceutical compositions comprising inhibitors of fab i and further antibiotics |
| 09/30/2004 | CA2519324A1 Medical devices with enhanced ultrasonic visibility |
| 09/30/2004 | CA2519310A1 Combined therapy comprising nemorubicin and a cyclooxygenase-2-inhibitor |
| 09/30/2004 | CA2519289A1 Nemorubicin as radiosensitizer in combination with radiation therapy against tumors |
| 09/30/2004 | CA2519125A1 Dispersible formulation of an anti-inflammatory agent |
| 09/30/2004 | CA2519002A1 Phenylcarboxyl acid amides and ikr channel inhibitors combination and the use thereof for treating atrial arrhythmia |
| 09/30/2004 | CA2517125A1 Methods for preparation and use of 1.alpha.,24(s)-dihydroxyvitamin d2 |
| 09/30/2004 | CA2516990A1 Treatment of alzheimer's disease |
| 09/30/2004 | CA2424053A1 Method of ameliorating side-effects of serms |
| 09/29/2004 | EP1462457A1 Cytotoxic protein and utilization thereof |